What is your experience with patients who receive bevacizumab plus a CT regimen? What types of issues/side effects do they report with treatment?
As I say, the combination of any chemotherapy with bevacizumab is really well-tolerated, and the side effects that we'll see have been principally limited to the side effects that we experience with the chemotherapy. That is, bevacizumab doesn't really contribute to side effects. If a side effect occurs, it's going to be in the form of hypertension, which will arise a few months after starting and if that were the case, I wouldn't necessarily change the regimen, but I would certainly provide treatment like an ACE inhibitor for the hypertension, which is usually quite effective.
We do check urine proteins periodically for patients on chemotherapy plus bevacizumab, and were there to be significant elevations in proteinuria, that might be a circumstance to discontinue or suspend the use of bevacizumab. Frankly, even there that's so uncommon that I can't even remember the last time I had to do that.
Unresectable Colon Cancer: Case 1
68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.
Sotorasib/Panitumumab Combo Improves PFS in Refractory KRAS G12C+ mCRC
October 23rd 2023The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Read More
T-IELs Could Hold the Key for CRC Immunotherapy
October 10th 2023Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.
Read More
CAPOX Regimen Appears Noninferior to FOLFOX in CRC
October 8th 2023The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.
Read More